Scope, Claims, and US Patent Landscape for Drug Patent 6,096,742
What does US Patent 6,096,742 actually claim?
US Patent 6,096,742 is centered on a single chemical entity defined by stereochemistry and substitution pattern, but locked to a specific polymorphic solid state using X-ray powder diffraction (XRPD) peak locations. The claims also create downstream coverage for form use in multiple therapeutic indications and for pharmaceutical formulations.
The patent defines a polymorphic form of the compound:
2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluoro)phenyl-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methylmorpholine)
Claim 1 then requires:
- the polymorphic form has XRPD key reflections at approximately
12.0, 15.3, 16.6, 17.0, 17.6, 19.4, 20.0, 21.9, 23.6, 23.8, and 24.8° (2θ)
- the material is substantially free of an alternative polymorphic form with a second XRPD fingerprint:
12.6, 16.7, 17.1, 17.2, 18.0, 20.1, 20.6, 21.1, 22.8, 23.9, and 24.8° (2θ)
The second polymorph is used as a negative limitation. This matters because it narrows infringement to products matching the first XRPD fingerprint while not being materially contaminated with the second.
Claim-by-claim scope
Below is the functional claim architecture and what each claim covers.
| Claim |
What is protected |
Core limitation(s) |
Practical enforcement target |
| 1 |
Polymorphic form of the active |
XRPD key reflections at ~12.0/15.3/…/24.8° and “substantially free” of the second XRPD pattern (12.6/16.7/…/24.8°) |
Solid-state product (API/Form) |
| 2 |
Pharmaceutical composition |
Claim 1 polymorph + pharmaceutically acceptable carrier + substantially free of the second polymorph |
Finished dosage forms and premixes that contain the specific form |
| 3 |
Use to block neurokinin-1 / antagonize substance P |
Administer polymorph of claim 1 in effective amount |
Combination and single-agent products positioned for NK1R blockade |
| 4 |
Treatment/prevention of emesis |
Administer polymorph of claim 1 |
Anti-emetic product labeling and regimen |
| 5 |
Treatment/prevention of depression (human) |
Administer polymorph of claim 1 |
CNS depression indication |
| 6 |
Treatment/prevention of anxiety (human) |
Administer polymorph of claim 1 |
Anxiety indication |
| 7 |
Treatment/prevention of psychosis (human) |
Administer polymorph of claim 1 |
Psychosis indication |
| 8 |
Treatment/prevention of schizophrenia (human) |
Administer polymorph of claim 1 |
Schizophrenia indication |
How tight is the polymorph definition (and why it matters)?
The enforceable hook is not merely the molecule; it is a specific XRPD fingerprint plus a negative restriction against a particular competing polymorph.
XRPD fingerprints in claim 1
Polymorph A (claimed) key reflections (~2θ):
12.0, 15.3, 16.6, 17.0, 17.6, 19.4, 20.0, 21.9, 23.6, 23.8, 24.8
Polymorph B (excluded; “substantially free” in claim 1) key reflections (~2θ):
12.6, 16.7, 17.1, 17.2, 18.0, 20.1, 20.6, 21.1, 22.8, 23.9, 24.8
Substantially free is a litigation lever
“Substantially free” is not quantified in the claim text provided. In practice, this becomes a testable issue:
- if a competitor’s material includes measurable B-polymorph contamination, the claim 1 “substantially free” requirement can be contested
- the closer a formulation sits to the boundary, the more XRPD test strategy, acceptance criteria, and sample handling become central
What is the “scope” of therapeutic coverage (claims 3 to 8)?
Claims 3 to 8 are method-of-use claims that require administration of the claim 1 polymorph. The indications are broad across CNS and clinical symptom domains.
Indication map
- NK1 / substance P blockade: claim 3
- Emesis: claim 4
- Depression: claim 5
- Anxiety: claim 6
- Psychosis: claim 7
- Schizophrenia: claim 8
Breadth implications
The method claims are written in “treatment or prevention” form and are not limited by dose, route, schedule, or patient subgroup in the claim language you provided. That increases practical scope for infringement arguments around:
- any regimen where the polymorphic form is the administered drug substance
- label-driven or off-label use within the stated indication categories
What parts of the patent do you use for freedom-to-operate (FTO)?
For FTO, the claim set breaks into two independent risk dimensions.
Dimension 1: solid-state compliance risk
If a product uses a different polymorph, it may fall outside claim 1 and claim 2. But claim 1 also contains the “substantially free” negative limitation, so “different but mixed” can still be risky.
What to track
- API polymorph identity (XRPD match to claimed A)
- presence/absence of B polymorph peaks and whether contamination exceeds what “substantially free” can tolerate
Dimension 2: use-based risk
Even if a product matches the polymorph definition, infringement of claims 3 to 8 can hinge on the product’s clinical positioning and use patterns.
What to track
- intended use and promotional claims tied to substance P/NK1 antagonism and the CNS indications listed
- clinical protocol language that maps to “treatment or prevention” for each indication
Where are the likely pressure points in enforcement?
The patent is built for solid-state differentiation, so the enforcement pressure points are:
-
XRPD peak matching
- the claim uses “approximately” and lists key reflections
- small shifts from instrument settings, sample prep, humidity history, grinding, and polymorph conversion risk become factual issues
-
“substantially free” of the excluded polymorph
- the excluded polymorph has its own distinctive peak set
- the harder it is to prove purity, the more discovery around manufacturing and testing matters
-
Linking the administered product to the claimed polymorph
- method claims require administration of the claim 1 polymorphic form
- for generics or branded competitors, the key question becomes whether their marketed API/form matches the claimed XRPD identity in practice
How does this shape the broader patent landscape (strategic read)?
Within the limited claim content provided, US 6,096,742 behaves like a classic polymorph “follow-on” patent:
- it claims a specific polymorphic form of an already-defined drug scaffold
- it then extends the form protection into composition and method-of-use territory
Strategic landscape effects
- For innovator portfolios: the polymorph patent can extend exclusivity by recapturing value even after earlier composition-of-matter scope expires or weakens.
- For generic entrants: generic design-around is less about changing the active substance and more about controlling the solid-state form and ensuring the marketed material is not the claimed polymorph (or not contaminated with it).
- For lifecycle management: the therapeutic claims make it easier to argue infringement even if a product has multiple indications, as long as its administered API matches the polymorph fingerprint.
Claim-scope matrix for competitor design-around
A competitor can be assessed on two axes: polymorph choice and indication posture.
| Competitor option |
Polymorph used |
XRPD risk vs claim 1 |
Indication risk vs claims 3-8 |
| Use exact claimed polymorph A |
A |
High |
High if used for listed indications |
| Use excluded polymorph B |
B |
Potentially low for claim 1/2 |
Still high only if a method claim is practiced with A (they wouldn’t be) |
| Use mixed material (A + B) |
Mixed |
High: claim 1 requires “substantially free” of B |
High if used for listed indications |
| Use another polymorph C not listed |
C |
Depends on XRPD overlap; A peaks can still appear in mixtures |
High if product is positioned for listed indications and contains A |
What is the scope of protection for competitors selling compositions? (Claim 2)
Claim 2 is a straightforward follow-on:
- a pharmaceutical composition with carrier
- containing the claim 1 polymorph
- and again requiring the composition is “substantially free” of the excluded polymorph
For product development and regulatory strategies, this means:
- even if the API matches, the finished dosage form must preserve the polymorphic identity sufficiently that it still meets claim 2’s XRPD-based purity requirement
Key Takeaways
- US 6,096,742 protects a single stereochemically defined drug but the real exclusivity is tied to a specific polymorphic XRPD pattern in claim 1.
- Claim 1 requires XRPD key reflections at about 12.0/15.3/16.6/17.0/17.6/19.4/20.0/21.9/23.6/23.8/24.8° (2θ) and prohibits material that is not substantially free of the alternative polymorph with peaks at about 12.6/16.7/17.1/17.2/18.0/20.1/20.6/21.1/22.8/23.9/24.8° (2θ).
- Claims 2 to 8 extend protection from the solid form into formulations and multiple method-of-use indications: NK1/substance P antagonism, emesis, and CNS disorders including depression, anxiety, psychosis, and schizophrenia.
- The enforceable risk for competitors concentrates on XRPD identity and impurity (polymorph contamination) and on whether the product is used or marketed for the listed therapeutic categories.
FAQs
1) Is the patent protecting the molecule or the polymorph?
The claim set is written to protect a polymorphic form defined by XRPD patterns. The molecule is defined as part of the polymorph identity, but infringement turns on meeting the XRPD fingerprint and the “substantially free” purity limitation.
2) Can a competitor avoid infringement by changing the polymorph?
A competitor can potentially avoid claim 1 and claim 2 by using a form that does not match the claimed XRPD key reflections and is not materially contaminated with the excluded polymorph. Mixed solid states can still create claim risk due to the “substantially free” language.
3) Do the therapeutic claims require the polymorph specifically?
Yes. Claims 3 to 8 require administering the polymorphic form of claim 1 in an effective amount for each therapeutic purpose.
4) Are the method claims limited by dose or route?
In the provided claim language, they are not limited by specific dose, route, or schedule; they broadly require administration of the claim 1 polymorph for the stated therapeutic objective.
5) What is the most likely technical dispute in litigation under this patent?
XRPD matching and polymorph purity: whether the accused material has the claimed A pattern and whether it is “substantially free” of the excluded B polymorph.
References
[1] US Patent 6,096,742.
